As a machine learning specialist, I have synthesized the key methodological advancements and findings from the provided abstracts. The current landscape of epitope mapping is undergoing a paradigm shift, moving from purely sequence-based or structure-based tools to **hybrid architectures** that leverage pre-trained Protein Language Models (PLMs) and Geometric Deep Learning.

The following mini-review summarizes the state-of-the-art in this field:

### 1. The Dominance of Protein Language Models (PLMs)
A recurring theme across the abstracts is the shift toward using large-scale pre-trained models—specifically **ESM-2** and **ProtBERT**—as the primary feature extractors (backbones).
*   **Feature Embedding:** Rather than relying solely on handcrafted amino acid properties, models like *DeepPhosPPI* and *DynaBCE* utilize PLM embeddings to capture complex evolutionary and biochemical contexts that are often missed by traditional methods.
*   **Transfer Learning:** These models allow for the transfer of knowledge from massive protein databases to specific tasks like epitope mapping, where experimental data is often scarce.

### 2. Methodological Innovation: Hybrid and Ensemble Architectures
The abstracts highlight a move toward multi-modal frameworks that combine different deep learning paradigms:
*   **Geometric Deep Learning:** For conformational B-cell epitopes (BCEs), sequence data alone is insufficient. The *DynaBCE* framework utilizes **Geometric Graph Neural Networks (GNNs)** to process structural descriptors, allowing the model to "understand" the spatial orientation of residues in 3D space.
*   **Attention-CNN and Transformers:** There is a clear trend of combining convolutional layers (for local spatial/sequence patterns) with Transformer blocks (for long-range dependencies). This is particularly effective in predicting how post-translational modifications, like phosphorylation, influence protein-protein interfaces.
*   **Dynamic Integration:** A significant finding in the *DynaBCE* study is that "dynamic ensemble" algorithms—which weight feature-based modules (PLMs/GNNs) and template-based modules (homology information) differently for each sample—outperform static models.

### 3. Key Findings in Epitope Categorization
The research distinguishes between the computational requirements for different epitope types:
*   **CD8+ T-Cell Epitopes:** Progress here focuses on the tripartite interaction between the peptide, MHC-I molecule, and TCR. PLM-based models are significantly increasing the efficiency of discovering these fragments for immunotherapy and vaccine design, moving beyond simple binding affinity to more complex recognition patterns.
*   **Conformational B-Cell Epitopes:** The primary challenge is the "native vs. predicted structure" gap. Modern methods (*DynaBCE*) are now achieving robust results even when using predicted (AlphaFold2-like) structures rather than experimentally determined native structures, broadening the utility of these tools in real-world drug discovery.

### 4. Expanding the Scope: Post-Translational Modifications (PTMs)
Epitope mapping is becoming more granular. The *DeepPhosPPI* research underscores that predicting interaction interfaces must now account for **phosphorylation**. Since phosphorylation can drastically alter the binding affinity of a protein surface, incorporating PTM-awareness into PLM-based frameworks is a critical new frontier for identifying "functional" epitopes in disease states like cancer.

### Summary for Implementation
For a practitioner, the evidence suggests that the most performant epitope mapping pipeline should:
1.  **Embed** sequences using **ESM-2** for rich evolutionary features.
2.  **Process** structures (if available) via **Geometric GNNs** to capture conformational signatures.
3.  **Integrate** a **template-based module** to leverage known structural homologs.
4.  **Apply** a **dynamic weighting mechanism** to synthesize these inputs, ensuring the model can handle both well-characterized and novel antigens.